Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

ARS-1620

Catalog No: tcsc0035119

Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Size: 100mg

Size: 200mg

Specifications

CAS No:
1698055-85-4

Formula:
$C_{21}H_{17}ClF_2N_4O_2$

Pathway:
GPCR/G Protein

Target:
Ras

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 53 mg/mL (123.02 mM)

Observed Molecular Weight:

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

430.84

Product Description

ARS-1620 is an atropisomeric selective **KRAS^{G12C}** inhibitor with desirable pharmacokinetics.

IC50 & Target: KRAS^{G12C}[1]

In Vitro: ARS-1620 is an atropisomeric selective KRAS^{G12C} inhibitor with desirable pharmacokinetics. ARS-1620 exhibits complete growth suppression of p.G12C cell lines (IC_{50}=150 nM) with relatively benign effects on control cell lines. It is found that ARS-1620 significantly reduces expression of the gene set in p.G12C mutant cells in a time-dependent manner but not in the p.G12S mutant cells. Following a 5-day treatment period, only a minority of G12C mutant cell lines are sensitive to ARS-1620 under monolayer culture conditions, whereas in 3D-spheroid conditions, ARS-1620 elicits a robust response (p=0.0140)[1].

In Vivo: Following a single oral dose or 5 consecutive daily doses, ARS-1620 yields average peak tumor concentrations of 1.5 μM (50 mg/kg) and 5.5 μM (200 mg/kg), respectively, that enables significant KRAS^{G12C} target occupancy (>=70% G12C-TE at 200 mg/kg) for >24 hr. In MIAPaCa2 xenografts (p.G12C), ARS-1620 significantly inhibits tumor growth (p